Suggestions
Christopher Ayres
Sr. Sales Specialist, Immunoassay Reagents @ Revvity
Christopher Ayres is a Senior Sales Specialist at Revvity based in the Greater Boston area.1 He supports drug discovery scientists with HTRF and AlphaLISA technologies.1 Christopher holds a degree from The College of William and Mary.1
As a sales specialist, Christopher likely works closely with pharmaceutical and biotechnology companies to provide solutions for their drug discovery and development needs. His expertise in HTRF (Homogeneous Time-Resolved Fluorescence) and AlphaLISA technologies suggests he specializes in assay development and screening tools used in early-stage drug research.
Given his role at Revvity, a company known for life sciences and diagnostics solutions, Christopher probably has a strong background in both science and business. His position involves understanding complex scientific concepts related to drug discovery while also possessing the sales and communication skills necessary to effectively present Revvity's products and services to potential clients.
Highlights
⭐ Today's assay spotlight: phospho-Tau T217 AlphaLISA ⭐
Biology background: Microtubule-associated protein Tau plays a key role in the pathogenesis of AD. Tau becomes hyperphosphorylated and aggregates, forming filaments, which can further condense into neurofibrillary tangles. Tau aggregates or “seeds” may propagate pathology by spreading from cell to cell in a “prion-like” manner. Drugs modulating Tau hyperphosphorylation and reducing tau aggregation are viable therapeutic approaches for treatment of AD.
Increased pTau-T217 levels are associated with Tau hyperphosphorylation and amyloid beta pathologies and is increasingly used as surrogate and diagnostic measurement for AD and associated pathologies.
Assay features: ▶ Quantify pTau-T217 in a wash-free format for minimal manipulation, improved CVs, and less time at the bench, ideal for high-throughput screening
▶ Massive dynamic range thanks to luminescent detection step -> bigger range = fewer repeat sample dilutions
▶ Sensitivity exceeding most conventional HRP-based assays
Link to assay in comments, or message me for the full suite of cellular validation work from Revvity R&D.
#revvity #AlphaLISA #unstoppableEAST
Fig.: SH-SY5Y cells were seeded at 20K cells/well in a 96 well plate, incubated for 96 hours, and treated with Staurosporine (a) at the indicated concentrations for 6 hours in media containing 1 % FCS. Cells were lysed with Lysis Buffer and assayed for various targets using respective SureFire Ultra kits. Equivalent to approximately 6,000 cells/datapoint.
⭐ Friday assay spotlight: phospho-TYK2 Alpha Surefire ⭐
Biology background: TYK2 is an intracellular tyrosine kinase member of the Janus kinase (JAK) family alongside JAK1, JAK2, and JAK3. TYK2 mediates signaling of a wide array of cytokines and growth factors including IL23, IL12, and type I IFN. Activated TYK2 subsequently phosphorylates additional targets, including both the cytokine receptors and the major substrates: STATs.
JAKs/STAT signaling stimulates cell proliferation, differentiation, migration, and apoptosis. Altering JAK/STAT signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies.
AlphaLISA features: ▶ Quantify phosphorylated or total TYK2 without wash steps -> less variability and time at the bench!
▶ Huge dynamic range, courtesy of the luminescent detection step -> fewer repeat sample dilutions!
▶ Sensitivity exceeding most "conventional" plate-based assays -> not naming names.
Thanks to the assay R&D team here at Revvity.
🌞 Happy Memorial Day weekend, everyone!
#revvity #AlphaLISA #unstoppableEAST
Fig.: THP1 cells were plated @ 200K cells/well in a 96-well plate and treated with IFNα at the indicated concentrations for 30 minutes. Cells were lysed with 5X Lysis Buffer and assayed separately for various targets using respective SureFire Ultra kits. Equivalent to approximately 8,000 cells/datapoint. Run concurrently with pSTAT Alpha Surefire assays for fuller pathway analysis.
